CN113727997A - 顽固性高血压的组合治疗 - Google Patents

顽固性高血压的组合治疗 Download PDF

Info

Publication number
CN113727997A
CN113727997A CN201980088279.4A CN201980088279A CN113727997A CN 113727997 A CN113727997 A CN 113727997A CN 201980088279 A CN201980088279 A CN 201980088279A CN 113727997 A CN113727997 A CN 113727997A
Authority
CN
China
Prior art keywords
manp
diuretic
mammal
polypeptide
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088279.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·小伯内特
N·德宙亚什维利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of CN113727997A publication Critical patent/CN113727997A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980088279.4A 2018-11-09 2019-11-08 顽固性高血压的组合治疗 Pending CN113727997A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758009P 2018-11-09 2018-11-09
US62/758,009 2018-11-09
PCT/US2019/060401 WO2020097421A1 (en) 2018-11-09 2019-11-08 Combination treatment for resistant hypertension

Publications (1)

Publication Number Publication Date
CN113727997A true CN113727997A (zh) 2021-11-30

Family

ID=70612496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088279.4A Pending CN113727997A (zh) 2018-11-09 2019-11-08 顽固性高血压的组合治疗

Country Status (13)

Country Link
US (2) US20220118054A1 (https=)
EP (2) EP4603090A1 (https=)
JP (2) JP2022506716A (https=)
KR (1) KR20210090229A (https=)
CN (1) CN113727997A (https=)
AU (2) AU2019375988A1 (https=)
BR (1) BR112021008841A2 (https=)
CA (1) CA3119055A1 (https=)
ES (1) ES3047085T3 (https=)
IL (2) IL282958B2 (https=)
MX (1) MX2021005453A (https=)
PL (1) PL3877402T3 (https=)
WO (1) WO2020097421A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240369535A1 (en) * 2021-09-07 2024-11-07 Mayo Foundation For Medical Education And Research METHODS AND MATERIALS FOR DETERMINING pGC TARGET DOSAGE
WO2023039453A2 (en) * 2021-09-09 2023-03-16 Mayo Foundation For Medical Education And Research Dual-function polypeptides and methods for use thereof
US20240116990A1 (en) * 2022-09-19 2024-04-11 Mayo Foundation For Medical Education And Research Compositions and Methods of Treatment Using CRRL 191
KR20250150650A (ko) * 2023-02-22 2025-10-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Manp를 이용한 대사증후군을 동반한 고혈압 치료 방법
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof
WO2025184377A1 (en) * 2024-02-28 2025-09-04 Mayo Foundation For Medical Education And Research Methods for sustained lowering of blood pressure using manp

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020899A1 (en) * 2014-03-14 2017-01-26 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (soc) diuretic treatment
WO2018089601A1 (en) * 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161521A (en) 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
KR930009516B1 (ko) 1990-04-27 1993-10-06 미쓰비시덴키 가부시키가이샤 진동검출기 및 그의 고유진동주파수 조정방법
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6969480B2 (en) 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
DE602005013244D1 (de) 2004-08-12 2009-04-23 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontroll
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
US20100266704A1 (en) 2008-12-15 2010-10-21 Novartis Ag Octreotide depot formulation with constantly high exposure levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020899A1 (en) * 2014-03-14 2017-01-26 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (soc) diuretic treatment
WO2018089601A1 (en) * 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHN C BURNETT等: "MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results", 《BMC PHARMACOL TOXICOL》, vol. 16, no. 1, pages 3 *
MCKIE PM等: "A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions", 《JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY》, vol. 54, no. 11, pages 1024 - 1032, XP026558169, DOI: 10.1016/j.jacc.2009.04.080 *

Also Published As

Publication number Publication date
IL282958B2 (en) 2025-01-01
US20250381249A1 (en) 2025-12-18
KR20210090229A (ko) 2021-07-19
AU2019375988A1 (en) 2021-05-27
IL315007A (en) 2024-10-01
EP3877402B1 (en) 2025-07-16
WO2020097421A1 (en) 2020-05-14
CA3119055A1 (en) 2020-05-14
IL282958B1 (en) 2024-09-01
EP3877402A1 (en) 2021-09-15
ES3047085T3 (en) 2025-12-03
MX2021005453A (es) 2021-09-08
JP2022506716A (ja) 2022-01-17
EP3877402A4 (en) 2022-07-27
JP2024156691A (ja) 2024-11-06
PL3877402T3 (pl) 2025-12-01
IL282958A (en) 2021-06-30
BR112021008841A2 (pt) 2021-08-31
AU2025203575A1 (en) 2025-06-05
EP4603090A1 (en) 2025-08-20
US20220118054A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US20250381249A1 (en) Combination treatment for resistant hypertension
US11897931B2 (en) MANP analogues
US20140066367A1 (en) Subcutaneous delivery of a long-acting natriuretic peptide
US10336803B2 (en) Insulin secreting polypeptides
CN120897752A (zh) 使用manp治疗高血压伴代谢综合征的方法
HK40061208A (en) Combination treatment for hypertension
HK40061208B (en) Combination treatment for hypertension
WO2025226690A1 (en) Methods and materials for using gc-a receptor activating peptides in combination with glp-1/gip receptor agonists
WO2025096051A1 (en) Miniaturized gc-a receptor activating peptides
WO2023039453A2 (en) Dual-function polypeptides and methods for use thereof
WO2025235379A1 (en) Polypeptides having natriuretic and insulin-secreting actions, and methods for their use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination